A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Budesonide/formoterol (Primary) ; Formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms Sophos
- Sponsors Pearl Therapeutics
- 19 Apr 2018 This trial has been completed in Spain(End date: 2018-04-04).
- 13 Apr 2018 This trial has been completed in Germany.
- 21 Mar 2018 Planned End Date changed from 1 Aug 2018 to 30 Mar 2018.